Rituximab and Interleukin-12 in Treating Patients With B-Cell Non-Hodgkin's Lymphoma

This study has been completed.

Study NCT00026182 Information provided by National Cancer Institute (NCI)

First Received: November 9, 2001 Last Updated: February 6, 2009 History of Changes

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Study Status:	This study has been completed.
Estimated Study Completion Date:	No date given
Primary Completion Date:	February 2008 (Final data collection date for primary outcome measure)

Publications:

Ansell SM, Geyer SM, Maurer MJ, Kurtin PJ, Micallef IN, Stella P, Etzell P, Novak AJ, Erlichman C, Witzig TE. Randomized phase II study of interleukin-12 in combination with rituximab in previously treated non-Hodgkin's lymphoma patients. Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):6056-63.

Ansell SM, Geyer SM, Witzig TE, et al.: NCCTG trial of concomitant or sequential IL-12 in combination with rituximab in previously treated non-Hodgkin lymphoma patients. [Abstract] J Clin Oncol 22 (Suppl 14): A-6591, 580s, 2004.

Ansell SM, Grote DM, Witzig TE, et al.: Lack of increased clinical efficacy when interleukin-12 is added to rituximab in B-Cell lymphoma patients is related to inadequate delivery of the cytokine to the sites of lymphoma. [Abstract] Blood 104 (11): A-1397, 2004.